Concepedia

Vladimir Galvao

VG

Statistics

Publications

7

Citations

254

H-Index

7

Active since

2022

Affiliations

Vall d'Hebron Institute of Oncology(Current)

Institut Gustave Roussy

Sarah Cannon

The University of Texas MD Anderson Cancer Center

Dana-Farber Cancer Institute

Vladimir Galvao is an author at Vall d'Hebron Institute of Oncology specializing in pharmacology, medicine, and oncology.

ORCID

Publications per year

2022–2025

7

Publications

7

Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial

Juanita Lopez, Thomas Powles, Fadi Braiteh et al. · Nature Medicine · 2025 · 96 citations · Full text

, , +8

Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors

María Vieito, Víctor Moreno, Anna Spreafico et al. · Clinical Cancer Research · 2023 · 77 citations

, , +17

BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas

Víctor Moreno, María Vieito, Juan Manuel Sepúlveda-Sánchez et al. · Nature Communications · 2023 · 26 citations · Full text

, , +13

SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001).

Antoine Hollebecque, Juanita Lopez, Sarina A. Piha‐Paul et al. · Journal of Clinical Oncology · 2023 · 16 citations

, , +17

Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors

Valentina Gambardella, Michael Ong, María E. Rodríguez-Ruiz et al. · Cancer Research Communications · 2025 · 16 citations · Full text

, , +17

1–5 of 7